Entrada Therapeutics, Inc. (TRDA)
About Entrada Therapeutics, Inc.
Entrada Therapeutics Inc is a clinical-stage biopharmaceutical company. It aims to transform the lives of patients by establishing a new class of medicines that engage intracellular targets that have long been considered inaccessible. The company's Endosomal Escape Vehicle (EEV)-therapeutics are designed to enable the efficient intracellular delivery into a variety of organs and tissues, resulting in an improved therapeutic index and protein-based programs for the potential treatment of neuromuscular and ocular diseases, among others. Its oligonucleotide programs are in development for the potential treatment of people living with Duchenne, which are exon 44, 45, 50, and 51 skipping amenable. It has partnered to develop a clinical-stage program, VX-670, for myotonic dystrophy type 1.
This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.
Financial summary
- Revenue FY2025
- $25.4M
- Net income
- -$143.8M
- Total assets
- $377.4M
- Market cap
- $247.3M
- Operating margin
- -621.1%
- Net margin
- -565.5%
Source: SEC EDGAR · updated Jun 7, 2026
Revenue & profit trend
Financial statements
Income statement
- Revenue
- $25.4M
- Operating expenses
- $183.3M
- Operating income
- -$157.9M
- Income tax
- $924.0K
- Net income
- -$143.8M
- EPS (basic)
- $-3.47
- EPS (diluted)
- $-3.47
Balance sheet
- Total assets
- $377.4M
- Current assets
- $306.3M
- Total liabilities
- $71.2M
- Current liabilities
- $24.5M
- Shareholders’ equity
- $306.1M
Cash flow
- Operating cash flow
- -$128.5M
- Investing cash flow
- $116.8M
- Financing cash flow
- $887.0K
- Net cash flow
- -$10.8M
Statements via Polygon.io (SEC filings)
15-minute delayed · data by Polygon.io
Past year · hover for prices
52-week range
- Market cap
- $247.3M
- EPS (diluted)
- $-3.47
- Shares outstanding
- 42.3M
- Open
- —
- Day range
- –
- Prev close
- —
- Volume
- —
- IPO date
- Oct 29, 2021
Entrada Therapeutics, Inc. (TRDA) Stock Price
- Reported a net loss of $143.8M in FY2025.
- Trading 64% below its 52-week high.
Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.
No reviews yet. Be the first to review Entrada Therapeutics, Inc..
Write a review
News about Entrada Therapeutics, Inc.
News & sentiment via Polygon.io
Entrada Therapeutics, Inc.: frequently asked questions
Is Entrada Therapeutics, Inc. an American company?
Entrada Therapeutics, Inc. is a US-based company headquartered in Boston, Massachusetts, listed in the americancompanies.com directory of American companies. Its American-origin credentials have not yet been independently verified.
Where is Entrada Therapeutics, Inc. headquartered?
Entrada Therapeutics, Inc. is headquartered in Boston, Massachusetts, United States.
Is Entrada Therapeutics, Inc. publicly traded?
Yes — Entrada Therapeutics, Inc. is a publicly traded company. Its stock trades under the ticker symbol TRDA on the NASDAQ.
What does Entrada Therapeutics, Inc. do?
Entrada Therapeutics, Inc. is an American Pharmaceuticals company in the Health & Beauty sector.
